Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Sequential Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of JNJ-28431754 in Otherwise Healthy Obese Male and Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Glucose intolerance; Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Johnson & Johnson
- 04 Jan 2013 New source identified and integrated (ClinicalTrials.gov record NCT01756404).
- 19 Oct 2010 New trial record